Jan de Witte is Director at RESMED INC (RMD). They have made 2 open-market trades across 2 companies since 2023, most recently 2025-11-25.
CIK 0001776929
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $300K since 2023, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RMD | SELL · 10b5-1 | 2025-11-25 | 2025-11-26 | $255.00 | $524K | -3.7% | -4.4% | -1.7% |
| RMD | SELL · 10b5-1 | 2025-11-11 | 2025-11-13 | $250.25 | $244K | +2.3% | +1.2% | +3.8% |
| RMD | SELL · 10b5-1 | 2025-05-20 | 2025-05-22 | $243.47 | $487K | +3.1% | +4.9% | +19.2% |
| RMD | SELL · 10b5-1 | 2024-11-12 | 2024-11-14 | $248.81 | $396K | +7.2% | +3.4% | +1.5% |
| RMD | SELL | 2024-05-15 | 2024-05-22 | $218.29 | $157K | -3.2% | -5.6% | +2.3% |
| IART | BUY | 2023-06-01 | 2023-06-02 | $38.50 | $300K | +3.0% | +3.7% | +7.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.